Day One Biopharmaceuticals Inc (DAWN) stock is down -77.37% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives DAWN stock a score of 25 out of a possible 100.
That rank is chiefly influenced by a long-term technical score of 3. DAWN's rank also includes a short-term technical score of 5. The fundamental score for DAWN is 65. In addition to the average rating from Wall Street analysts, DAWN stock has a mean target price of $32.67. This means analysts expect the stock to climb 457.44% over the next 12 months. DAWN has an Overall Score of 25. Find out what this means to you and get the rest of the rankings on DAWN!